地舒单抗生物类似药 (Celltrion): 一种RANKL抑制剂药物,由Celltrion, Inc. (Celltrion, Inc.)公司最早进行研发,目前全球最高研发状态为批准上市,作用机制: RANKL抑制剂(肿瘤坏死因子配体超家族成员11抑制剂),治疗领域: 肿瘤,内分泌与代谢疾病,皮肤和肌肉骨骼疾病,在研
These data provide evidence that inhibition of RANKL, in this case by its natural inhibitor OPG, can have clinically measurable effects. However, the development of OPG as a therapy for osteoporosis was not pursued because of its potential immunogenicity, because immunologic resistance to OPG could ...
we report an approach to identify a small molecular binding site to selectively inhibit the interaction of soluble RANKL and RANK for designing anti-osteoporosis drugs without undesirable immunosuppressive effects. Through molecular
RANKL抑制剂地诺塞麦所致颌骨坏死 Hans Journal of Surgery 外科, 2014, 3, 1-5 http://dx.doi.org/10.12677/hjs.2014.31001Published Online January 2014 (http://www.hanspub.org/journal/hjs.html) OPEN ACCESS 1 Denosumab, a RANKL Inhibitor, Induced Osteonecrosis of the Jaw* Longwei Hu1, Liqun...
Nevertheless, RANKL-inhibitor therapies fail to consider the biological effects of disrupting RANKL binding to LGR4. While the role of the RANKL/RANK signaling pathway in stemness, tumor promotion, and metastasis have been thoroughly elucidated, the precise function of RANKL through its interaction ...
Denosumab, a RANKL Inhibitor, Induced Osteonecrosis of the Jaw* Longwei Hu1, Liqun Xu2# 1College of Stomatology, School of Medicine, Shanghai Jiao Tong University, Shanghai 2Department of Oral and Maxillofacial Surgery, The Ninth People’s Hospital, Shanghai Jiao Tong University School of ...
引起药物性颌骨坏死的主要两大类药物包括双磷酸盐及RANKL抑制剂。RANKL抑制剂地诺塞麦是一种完全人化单克隆抗体,临床上主要用于预防实体肿瘤发生骨转移患者骨相关事件的发生以及用于增加骨质疏松患者的骨密度。本文就地诺塞麦的作用机制、临床应用、副作用,与双磷酸盐比较
除了细胞毒性药物和内分泌干扰药物【endocrine disruptive drugs】外,靶向 RANK/RANKL/OPG 轴的疗法通过阻断骨和癌细胞之间的恶性循环【by blocking the vicious cycle between bone and cancer cells 】表现出直接和/或间接的抗肿瘤作用 (89...
Clinical trials investigating combination of immune checkpoint inhibitors with drugs inhibiting the RANK–RANKL system. Cancer typeDrug inhibiting RANK–RANKLImmune checkpoint inhibitorPrimary endpointClinicalTrials.gov registration # Melanoma (unresectable, stage III/IV) Denosumab Nivolumab or ipilimumab-...
In addition, noggin is an endogenous inhibitor of BMPs that can bind to BMP-2 and block the interaction between BMP-2 and its receptors[19]. Moreover, noggin dose- dependently decreased osteoclast formation in vitro[20]. Over- expression of noggin clearly impaired osteoclast formation and ...